Roche Rocephin injection for otitis media approved Dec. 23 as first single-dose regimen for indication.
Executive Summary
ROCHE ROCEPHIN IS FIRST SINGLE-DOSE OTITIS MEDIA ANTIBIOTIC following approval of Roche's supplemental NDA 50-585/S-046 by FDA on Dec. 23. The new indication for Rocephin (ceftriaxone) intramuscular injection covers acute otitis media due to Streptococcus pneumoniae and beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis. The 13 other antibiotics approved for otitis media are all orally administered and require a five- to 10-day dosing regimen, which can complicate compliance.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth